Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 6
1975 1
1976 4
1977 4
1978 5
1979 2
1981 3
1982 3
1983 8
1984 6
1985 3
1986 2
1987 6
1988 6
1989 13
1990 7
1991 6
1992 18
1993 18
1994 14
1995 25
1996 22
1997 33
1998 39
1999 28
2000 46
2001 57
2002 51
2003 78
2004 91
2005 97
2006 97
2007 114
2008 145
2009 143
2010 207
2011 235
2012 246
2013 257
2014 365
2015 339
2016 385
2017 411
2018 484
2019 545
2020 683
2021 745
2022 870
2023 875
2024 328

Text availability

Article attribute

Article type

Publication date

Search Results

7,270 results

Results by year

Filters applied: . Clear all
Page 1
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Platzbecker U, et al. Among authors: wan y. Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048786 Clinical Trial.
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W, Zhang Y, Wan Y, Li W, Song W, Wang ZM, Li B, Xia M, Yang Y, Fang W, Huang Y, Zhang L. Zhao Y, et al. Among authors: wan y. EClinicalMedicine. 2023 Aug 3;62:102106. doi: 10.1016/j.eclinm.2023.102106. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37593227 Free PMC article.
Hydrogel-Based Sensors for Human-Machine Interaction.
Fang K, Wan Y, Wei J, Chen T. Fang K, et al. Among authors: wan y. Langmuir. 2023 Dec 5;39(48):16975-16985. doi: 10.1021/acs.langmuir.3c02444. Epub 2023 Nov 23. Langmuir. 2023. PMID: 37994525 Review.
DNASE1L3 enhances antitumor immunity and suppresses tumor progression in colon cancer.
Li W, Nakano H, Fan W, Li Y, Sil P, Nakano K, Zhao F, Karmaus PW, Grimm SA, Shi M, Xu X, Mizuta R, Kitamura D, Wan Y, Fessler MB, Cook DN, Shats I, Li X, Li L. Li W, et al. Among authors: wan y. JCI Insight. 2023 Sep 8;8(17):e168161. doi: 10.1172/jci.insight.168161. JCI Insight. 2023. PMID: 37581941 Free PMC article.
Untangling the web of intratumor microbiota in lung cancer.
Liu W, Xu J, Pi Z, Chen Y, Jiang G, Wan Y, Mao W. Liu W, et al. Among authors: wan y. Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):189025. doi: 10.1016/j.bbcan.2023.189025. Epub 2023 Nov 20. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37980944 Review.
7,270 results